"Awakening" From Schizophrenia: Intramolecular Polypharmacy and the Atypical Antipsychotics
J Clin Psychiatry 1997;58(9):381-382
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Is the ideal antipsychotic a soloist or a member of a large ensemble? The earliest antipsychotic melody of D2 receptor antagonism was embedded in a cacophony of jackhammering antihistamines, screeching anticholinergics, and droning α-antagonists. This molecular noise is somewhat filtered by high-potency antipsychotics, but the emerging dopamine antagonist theme song is too loud, grating on nerves, especially extrapyramidal ones.